Omeros (NASDAQ:OMER) Cut to Sell at Wall Street Zen

Omeros (NASDAQ:OMER) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other analysts have also recently weighed in on the company. HC Wainwright increased their price objective on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. WBB Securities restated a “strong-buy” rating and issued a $45.00 price target on shares of Omeros in a research note on Wednesday, October 15th. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 target price on shares of Omeros in a report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Omeros Stock Down 7.1%

OMER opened at $12.49 on Friday. Omeros has a 52 week low of $2.95 and a 52 week high of $17.65. The business’s 50 day moving average is $10.58 and its two-hundred day moving average is $6.64. The firm has a market cap of $885.54 million, a price-to-earnings ratio of -6.18 and a beta of 2.38.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.39. Equities analysts expect that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Omeros

Institutional investors have recently bought and sold shares of the stock. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Omeros during the 2nd quarter worth $32,000. Harbour Investments Inc. grew its stake in shares of Omeros by 46.1% in the second quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 4,251 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 11,971 shares during the period. Sei Investments Co. acquired a new position in Omeros during the 2nd quarter worth approximately $40,000. Finally, Russell Investments Group Ltd. boosted its holdings in Omeros by 113.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 5,677 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: HC Wainwright sharply raised its price target to $40 and kept a Buy rating, highlighting large upside vs. the current share level — this upgrade is a clear bullish catalyst. HC Wainwright PT raise
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating with a $36 price target, providing additional analyst support for upside. D. Boral Capital reaffirmation
• Positive Sentiment: Omeros announced pricing for YARTEMLEA at $36,000 per single‑dose vial — a premium price that boosts near‑term revenue potential for its recently approved transplant complication therapy. Reuters: pricing
• Positive Sentiment: Company comments on FDA approval and commercialization plans for YARTEMLEA underline management’s readiness to commercialize and support uptake, which can validate the higher price target narratives. Seeking Alpha transcript
• Neutral Sentiment: HC Wainwright published detailed near‑term EPS forecasts (Q1–Q4 2026 showing losses) while projecting a large turnaround by FY2030 (EPS $6.69); this signals long‑term optimism but acknowledges multi‑year losses.
• Neutral Sentiment: Needham reiterated a Hold rating, reflecting balanced risk/reward as YARTEMLEA ramps. Needham Hold note
• Neutral Sentiment: There was a reported after‑hours bounce recently, indicating volatile trading around the approval/pricing news rather than steady directional conviction. MSN after‑hours
• Negative Sentiment: Near‑term financials remain loss‑making (consensus and HC Wainwright 2026 EPS estimates are negative), which can pressure the stock until commercial execution and revenue ramp are proven.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.